U.S. Markets close in 3 hrs 59 mins

GlaxoSmithKline says FDA approves new indication for Promacta

GlaxoSmithKline (GSK) announced that the U.S. Food and Drug Administration has approved Promacta for the treatment of thrombocytopenia, or low blood platelet counts, in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. There are limitations to the use of PROMACTA in patients suffering from chronic hepatitis C-associated thrombocytopenia, the company noted.